Wilson's disease (WD) is a rare autosomal recessive disorder characterized by the deposition of copper mainly in the liver or nerve system that leads to their dysfunction. Mutations in the gene encoding ATPase, Cu+ transporting, beta polypeptide (ATP7B) are causative for WD. The aim of this study was to develop a rapid and convenient assay for detection of the three most common causative ATP7B mutations, p.R778L, p.P992L, and p.V1106I. 
treatment can decrease the rates of disability or mortality and lead to better prognoses.
The gene responsible for WD is located in the 13q14.3 chromosome and encodes a copper-specific transporting P-type ATPase (ATP7B). 4 Mutations in the ATP7B gene change the biosynthetic and transporting role of ATPase in cells, leading to impaired biliary excretion of copper. To date, more than 500 ATP7B mutations have been identified, and more than 70% of WD cases are associated with an ATP7B mutation [WD Mutation Database (http://www.wilsondisease.med.
ualberta.ca/database.asp) and Human GeneMutation Database (http:// www.hgmd.org/)]. Reported mutations in ATP7B include missense mutations, frameshift mutations, nonsense mutations, and splicing mutations, and missense mutations are the most common ATP7B mutation in WD. Among these mutations, p.Arg778Leu (c.2333G>T) has been identified as the most common. Both p.Pro992Leu (c.2975C>T) and p.Val1106Ile (c.3317G>A) are also relatively frequent mutations in WD, and also play important roles in the detection of WD. [5] [6] [7] Various approaches have been described for the detection of ATP7B gene mutations, such as multi-allele genotyping, genotyping microarray, and Sanger sequencing, but the clinical uses of these approaches are limited. 8, 9 Recently, high-resolution melting (HRM) analysis was developed as a closed-tube technology for genotyping DNA variants and mutation screening, with advantages over other techniques such as its high-throughput, rapid, and nondestructive nature. 10 However, amplicon melting analysis of HRM cannot always differentiate homozygous mutations from wild-type, particularly in cases where the mutation results in the insertion of a complementary base and the bases closest to the mutation are identical on both strands (nearest-neighbor thermodynamics symmetry). 11 The use of an unlabeled probe confers an added degree of sequence specificity desirable for clinical application. The Tm shift induced by a mutation depends on the binding strength between the mutated base and its counterpart on the opposite strand, as well as nearest-neighbor effects. Incorporation of locked nucleic acids (modified bases) into the probe may increase the ability to discriminate different sequence variants. [12] [13] [14] Thus, these modifications could satisfy the clinical demand of developing a simple and accurate method for the detection of ATP7B gene mutations with high specificity and sensitivity.
In this study, we reported a novel method based on the use of HRM analysis and unlabeled probes to rapidly genotype the three most common variants of the ATP7B gene in a clinical laboratory setting.
| MATERIALS AND METHODS

| Plasmid construction
Part of the ATP7B gene was amplified by polymerase chain reaction seconds. An additional 3-minute extension at 72°C was performed after the last PCR cycle to replenish PCR product followed by cooling at 4°C. The PCR product was then cloned into the pMD19-T-simple cloning vector as described by the manufacturer's instructions (Takara, Dalian, China), and the construct was confirmed by DNA sequencing.
| Primers and probes
Primers and probes were designed with Primer 5 software ( Table 1) .
Unlabeled nucleotide probes bind to the negative strand of wild allele at the three loci, respectively, with ~40 GC content (except the ATP7B 992 probe). A 3′ amino modifier (AmM) was incorporated to prevent extension during the PCR reaction.
| Unlabeled probe HRM analysis
Asymmetric PCR amplification was performed in a 96-well plate 
| Samples
Blood samples were collected from 41 patients at the Beijing Friendship
Hospital and with informed consent. Genomic DNA was extracted using the QIAamp DNA mini kit (Hilden, Germany) and eluted in 50 μL elution buffer. Quantification of all DNA samples was performed using the NanoDrop ™ 8000 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and checked by conventional PCR using the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase as a reference.
| Statistical analysis
Melting data were analyzed using the LightCycler 480 Software SW1.5
(Roche Applied Science) and the MeltingWizard High-Resolution
Melting Analysis vMW4.1 software (University of Utah). 15 For reproducibility studies, intra-run reproducibility was performed using six samples representing three genotypes. These samples were assessed in triplicate within a common run. Inter-run reproducibility was performed with six samples representing three genotypes. These samples were analyzed in five runs on different days. Precision was measured by the standard deviation (SD) of the melting temperature (Tm) and the SD of the Tm differences (ΔTm) between alleles. All statistical analyses were performed using SPSS 16.0 software (SPSS Inc., Chicago, IL, USA).
| RESULTS
| Construction plasmids of different genotypes of ATP7B
To assess the use of unlabeled probe HRM analysis for genotyping the three most common variants of the ATP7B gene in WD (R778L, P992L, and V1106I), we amplified fragments corresponding to these different genotypes and subcloned the fragments into T&A cloning vectors.
These plasmids were used as templates for HRM assays using the corresponding primers in Table 1 . Sequences of the wild-type ATP7B gene and the three variants, as well as the location of the primers and probes, are shown in Fig. 1 . All of the plasmids were confirmed by sequencing.
| Detection of different genotypes by unlabeled probe HRM assay
We next performed unlabeled probe HRM assays for all three variants. As shown in Fig. 2 , the melting peaks include both the probe represents the R778L mutation, while the melting peak at 76.40°C
represents the wild-type (Fig. 2a) . The melting peak at 77.20°C
represents the P992L mutation, while the melting peak at 82.00°C
represents the wild-type (Fig. 2b) . The melting peak at 66.50°C represents the V1106I mutation, while the melting peak at 71.10°C represents the wild-type (Fig. 2c ).
The controls with no templates showed no peaks, and the amplicon melting peaks did not interfere with the probe melting peaks.
| Repeatability of the unlabeled probe HRM assay
To determine within-run reproducibility, wild-type plasmids, homozygous plasmids, and heterozygous plasmids (mixed wild-type and homozygous plasmids) of different variants were tested in triplicate in one run. The averaged Tm and delta Tm for different genotypes were described in Table 2 .
The between-run reproducibility was tested using the same plasmids as in the within-run reproducibility test. The assays were run five consecutive times and the Tm values from each run were averaged (Table 2) .
| Clinical evaluation for accuracy of the unlabeled probe HRM assay
We further assessed our method in clinical specimens containing different variants. When clinical samples with the indicated genotypes were subject to the unlabeled probe HRM analyses, the melting patterns were consistent with those obtained from plasmid DNA templates (Fig. 3) . The averaged Tm and delta Tm for different genotypes are described in Table 3 .
The results were further verified by sequencing and were found to be consistent with those of the unlabeled probe HRM assay (correct genotyping rates were 100%).
| DISCUSSION
Wilson's disease is an autosomal recessive inheritance disorder of copper metabolism. Early diagnosis and treatment are associated with better outcome. However, current diagnostic criteria are based on symptoms and copper detection. Patients with mild symptoms may be misdiagnosed, resulting in delayed treatment. Genetic testing of the ATP7B gene mutation may lead to reliable early diagnosis and treatment, which can prevent copper accumulation and tissue damage.
16
The methods currently used to detect ATP7B mutation include multiallele genotyping, genotyping microarray, and Sanger sequencing, but the clinical use of these approaches are limited. HRM analysis has emerged as a rapid and sensitive method for mutation scanning as well as targeted single-nucleotide polymorphism genotyping. 17 In HRM, samples can be genotyped by Tm as well as curve shape, and the amplification products from different genotypes can be resolved by melt analysis. However, HRM can be affected by such factors as sequence length and mutation type, and sometimes HRM cannot detect homozygous mutations with a small difference in Tm. 18 Therefore, HRM is also characterized by poor sensitivity and specificity. To overcome this disadvantage, a method based on fluorescently labeled probe assays was developed. However, this approach requires two sets of fluorescently labeled probes and employs fluorescent resonance energy transfer in the LightCycler platform, which is costly and royalty bearing. 19 The unlabeled probe HRM technique was developed as a novel approach by integrating HRM with asymmetric PCR using an unlabeled modified base probe, which facilitated detection of mutation sites and added the sequence specificity desirable for clinical applications.
20-22
The unlabeled probe HRM assays use ~30 bp C3 blocked probes to target the site of interest during the melting process. A single base pair difference in such a short probe can result in a significant Tm shift (e.g., 3-5°C). Genotyping with unlabeled probes has been successfully applied for the detection of disease-related single nucleotide polymorphisms such as factor V Leiden, and the detection and genotyping of herpes simplex virus. 15, 22 The probe melting temperatures (Tm) from within-run and between-run showing averaged Tms, difference between melting temperatures (ΔTm) for heterozygotes, standard deviations (SD, in parentheses), and coefficient of variation (CV) are listed. N/A, not available (only one sample with this genotype was run, thus SD and CV could not be calculated).
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